Evaluation of the pain matrix using EEG source localization: a feasibility study.
The areas that were activated in the high pain state localized to the same regions reported by other neuroimaging methods and with frequency specificity. The frequency and regionally specific activation may indicate distinctive patterns of pathophysiology underlying the pain matrix. Although in a small number of patients, this work suggests that QEEG may be a useful tool in the exploration and quantification of the pain matrix in a clinical setting.
PainQx Accepted Into the Digital Health Accelerator
Launched in 2014 by the Science Center, the DHA supports early-stage digital health companies with funding, office space, professional mentorship and introductions to key healthcare stakeholders in the Greater Philadelphia region. The DHA has received support from the Commonwealth of Pennsylvania’s Department of Community and Economic Development and the U.S. Small Business Administration Growth Accelerator Fund.
Mid Atlantic Bio Angels Invests in PainQx
Mid Atlantic Bio Angels (MABA) announces today that it has made an investment in New York and Philadelphia-based PainQx, Inc., which has developed an accurate and objective method to measure chronic and acute pain in humans.
PainQx Accepted into Mass Challenge
May 30th, 2017
PainQx has been accepted into the Mass Challenge Accelerator. MassChallenge, the most startup-friendly accelerator on the planet, today announced the 128 early-stage startups that have been accepted into the 2017 MassChallenge Boston accelerator program. Selected by a community of more than 850 expert judges, this year’s competitive cohort represents the top 8% of applications from around the world, including 12 countries and 16 U.S. states.
Winner of NIDA Challange Program
November 22nd 2016
The National Institute on Drug Abuse (NIDA), one of the components of the National Institutes of Health (NIH), announces the “$100,000 for Start a SUD Startup” Challenge. The Challenge goal is to support research ideas that would further an understanding of neurobiology as it relates to Substance Use Disorders (SUD) and that are intended to be the basis for the development of a new and potentially successful start-up.
DocCheck News: Measuring pain: MegaPain 2 deep
February 9th 2016
In a clinical world that increasingly relies more on computerized medical technique, however, there are inconveniences that outweigh any mechanical analysis. Different strategies try to make measurable pain - with surprisingly good results.
PM360: Innovators 2015 Startups PainQx
December 15th 2015
Here are our picks for the most innovative startups of 2015, which include companies less than five years old pioneering new avenues in healthcare.
MedCity News: How Much Does it Hurt? Startup’s Device Objectively Measures Pain
June 10th 2015
Is pain subjective? Does one person feel it the same way as another? In general clinical practice, we don’t really know. Right now, our approach to gauging how much something hurts is rudimentary at best – a 0-10 pain scale.